

Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations - Global Forecast to 2028

Market Report | 2024-01-30 | 194 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global theranostics market is projected to reach USD 4.3 billion by 2028 from USD 2.1 billion in 2023, at a CAGR of 15.5% from 2023 to 2028. Factors such as rising baby boomer population and advances in research and development of radiopharmaceuticals are responsible for the increasing growth of this market. Increasing research and development activities, rising number of clinical trials, and government initiatives attributes to the growth of theranostics market.

"The radiopharmaceuticals segment held the largest share of the market in 2022."

Based on product, the theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/biomarker screening, and software and services. The radiopharmaceuticals segment held the largest market share in 2022. The large share of this segment can be attributed to the rising adoption of theranostics and increasing prevalence of chronic diseases such as cancer.

"The prostate cancer application segment is projected to register the highest CAGR of the theranostics market by application during the forecast period."

Based on application, the theranostics market is segmented into prostate cancer, bone metastasis, other cancer, and other applications. The prostate cancer application segment is projected to register the highest CAGR of the theranostics market from 2023 to 2028. Factors such as rising number of cancer population and ongoing clinical trials to know the benefits of theranostics for other applications are driving the market growth.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"The market in the Asia Pacific region is expected to witness the highest growth during the forecast period."

The theranostics market in the APAC region is expected to register the highest CAGR during the forecast period, primarily due to evolving healthcare infrastructure and increasing focus of major players in the region. The healthcare infrastructure in emerging economies, such as China and India is evolving at a rapid pace, leading to major investments by hospitals and other end users. These factors are anticipated to fuel the growth of theranostics market in this region.

A breakdown of the primary participants referred to for this report is provided below:

- By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%
- By Designation: Director-level-14%, C-level-10%, and Others-76%
- By Region: North America-40%, Europe-32%, Asia Pacific-20%, Rest of the World- 8%

The prominent players in the theranostics market Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US) among others.

Research Coverage

This report studies the theranostics market based on product, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their growth trends and forecasts the revenue of the market segments with respect to three main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall theranostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

- Analysis of key drivers (growing geriatric population and rising prevalence of associated diseases, rising use of radiopharmaceuticals, rising focus on precision medicine), restraints (short life of radiopharmaceuticals, unfavourable reimbursement scenario), opportunities (growth opportunities in emerging countries, advances in research and development of radiopharmaceuticals), and challenges (hospital budget cuts and high equipment costs) influencing the growth of the theranostics market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the theranostics market
- Market Development: Comprehensive information about lucrative markets-the report analyses the theranostics market across varied regions
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the theranostics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US).

Table of Contents:

- 1□INTRODUCTION□22
- 1.1□STUDY OBJECTIVES□22
- 1.2□MARKET DEFINITION□22

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.3	INCLUSIONS & EXCLUSIONS	22
1.4	MARKET SEGMENTATION	23
1.4.1	MARKETS COVERED	23
1.4.2	REGIONS COVERED	23
1.4.3	YEARS CONSIDERED	24
1.4.4	CURRENCY CONSIDERED	24
1.5	RESEARCH LIMITATIONS	24
1.6	STAKEHOLDERS	25
1.7	RECESSION IMPACT: THERANOSTICS MARKET	25
2	RESEARCH METHODOLOGY	26
2.1	RESEARCH DATA	26
FIGURE 1	RESEARCH DESIGN METHODOLOGY	26
2.1.1	SECONDARY DATA	27
2.1.2	PRIMARY DATA	28
2.1.2.1	Primary sources	28
2.1.2.2	Key industry insights	29
2.1.2.3	Breakdown of primaries	29
FIGURE 2	BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	29
FIGURE 3	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	30
2.2	MARKET SIZE ESTIMATION	30
FIGURE 4	RESEARCH METHODOLOGY: HYPOTHESIS BUILDING	31
2.2.1	BOTTOM-UP APPROACH	31
2.2.1.1	Approach 1: Company revenue estimation approach	32
FIGURE 5	COMPANY REVENUE ESTIMATION	32
FIGURE 6	REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF BAYER AG	33
2.2.1.2	Approach 2: Patient population-based market estimation	33
FIGURE 7	BOTTOM-UP APPROACH: THERANOSTICS MARKET	34
2.2.1.3	Growth forecast	34
2.2.1.4	CAGR projections	35
FIGURE 8	CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	35
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	35
FIGURE 9	DATA TRIANGULATION METHODOLOGY	36
2.3.1	MARKET SHARE ESTIMATION	36
2.4	STUDY ASSUMPTIONS	37
2.4.1	MARKET ASSUMPTIONS	37
2.4.2	GROWTH RATE ASSUMPTIONS	37
2.5	RISK ASSESSMENT	38
TABLE 1	RISK ASSESSMENT: THERANOSTICS MARKET	38
2.6	IMPACT OF ECONOMIC RECESSION ON THERANOSTICS MARKET	38
3	EXECUTIVE SUMMARY	39
FIGURE 10	THERANOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	39
FIGURE 11	THERANOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	40
FIGURE 12	THERANOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	40
FIGURE 13	REGIONAL SNAPSHOT OF THERANOSTICS MARKET	41
4	PREMIUM INSIGHTS	42
4.1	THERANOSTICS MARKET OVERVIEW	42
FIGURE 14	RIISING PREVALENCE OF CANCER AND GROWING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET	42

4.2	NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT (USD MILLION)	43
FIGURE 15	RADIOPHARMACEUTICALS TO COMMAND LARGEST MARKET SHARE IN NORTH AMERICAN THERANOSTICS MARKET DURING FORECAST PERIOD	43
4.3	EUROPE: THERANOSTICS MARKET, BY APPLICATION (USD MILLION)	44
FIGURE 16	PROSTATE CANCER TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD	44
4.4	ASIA PACIFIC: THERANOSTICS MARKET, BY END USER (USD MILLION)	44
FIGURE 17	HOSPITALS AND CANCER CARE CENTERS TO COMMAND LARGEST SHARE IN ASIA PACIFIC MARKET DURING FORECAST PERIOD	44
4.5	GEOGRAPHIC SNAPSHOT: THERANOSTICS MARKET	45
FIGURE 18	CHINA TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD	45
5	MARKET OVERVIEW	46
5.1	INTRODUCTION	46
5.2	MARKET DYNAMICS	46
FIGURE 19	DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: THERANOSTICS MARKET	46
5.2.1	DRIVERS	47
5.2.1.1	Growing geriatric population and rising prevalence of target diseases	47
5.2.1.2	Increasing use of radiopharmaceuticals in neurological applications	47
5.2.1.3	Growing focus on precision medicine	47
5.2.2	RESTRAINTS	48
5.2.2.1	Short half-life of radiopharmaceuticals	48
TABLE 2	PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS	48
5.2.2.2	Unfavorable healthcare reimbursement scenario	49
5.2.3	OPPORTUNITIES	49
5.2.3.1	Growth opportunities in emerging economies	49
5.2.3.2	Rising number of R&D programs for radiopharmaceuticals	49
5.2.4	CHALLENGES	50
5.2.4.1	Hospital budget cuts and high equipment costs	50
5.3	PRICING ANALYSIS	50
FIGURE 20	AVERAGE SELLING PRICE FOR RADIOPHARMACEUTICALS	51
TABLE 3	AVERAGE COST FOR THERANOSTICS TREATMENT, BY REGION	52
5.4	VALUE CHAIN ANALYSIS	52
FIGURE 21	VALUE CHAIN ANALYSIS: THERANOSTICS MARKET	52
5.5	ECOSYSTEM/MARKET MAP	53
5.6	SUPPLY CHAIN ANALYSIS	53
5.6.1	PROMINENT COMPANIES	53
5.6.2	SMALL & MEDIUM-SIZED ENTERPRISES	54
5.6.3	END USERS	54
FIGURE 22	SUPPLY CHAIN ANALYSIS: THERANOSTICS MARKET	54
5.7	PORTER'S FIVE FORCES ANALYSIS	54
TABLE 4	PORTER'S FIVE FORCES ANALYSIS: THERANOSTICS MARKET	55
5.7.1	INTENSITY OF COMPETITIVE RIVALRY	55
5.7.2	BARGAINING POWER OF SUPPLIERS	55
5.7.3	BARGAINING POWER OF BUYERS	55
5.7.4	THREAT OF SUBSTITUTES	56
5.7.5	THREAT OF NEW ENTRANTS	56
5.8	REGULATORY LANDSCAPE	56
5.8.1	NORTH AMERICA	56

5.8.1.1	US	56
5.8.1.2	Canada	56
5.8.2	EUROPE	57
5.8.3	ASIA PACIFIC	57
5.8.3.1	Australia	57
5.8.3.2	India	57
5.8.3.3	China	58
5.8.4	REST OF THE WORLD	58
5.8.4.1	Turkey	58
5.8.4.2	UAE	58
5.8.4.3	South Africa	58
TABLE 5	REGULATORY AGENCIES AND GUIDELINES	59
5.9	TIMELINE FOR THERANOSTICS MARKET	61
5.10	REIMBURSEMENT ANALYSIS	61
TABLE 6	MEDICAL REIMBURSEMENT CODES FOR THERANOSTICS IN US, 2022	62
5.11	TRADE ANALYSIS	62
5.11.1	TRADE ANALYSIS FOR THERANOSTICS MARKET	62
TABLE 7	IMPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2022 (USD THOUSAND)	62
TABLE 8	EXPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2022 (USD THOUSAND)	63
5.12	PATENT ANALYSIS	64
FIGURE 23	TOP 10 PATENT APPLICANTS FOR THERANOSTICS (JANUARY 2012-DECEMBER 2022)	64
5.13	CASE STUDY ANALYSIS	65
TABLE 9	CASE STUDY 1: LUTETIUM-177-PSMA-617 FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER	65
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	65
5.14.1	KEY STAKEHOLDERS	65
TABLE 10	KEY STAKEHOLDERS AND THEIR REQUIREMENTS	65
5.14.2	IMPACT ANALYSIS OF KEY BUYING CRITERIA	66
TABLE 11	IMPACT OF KEY STAKEHOLDERS ON BUYING CRITERIA	66
5.15	KEY CONFERENCES & EVENTS	69
TABLE 12	LIST OF KEY CONFERENCES & EVENTS, 2023-2024	69
5.16	CLINICAL RESEARCH DATA FOR THERANOSTICS MARKET	70
6	THERANOSTICS MARKET, BY PRODUCT	73
6.1	INTRODUCTION	74
TABLE 13	THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	74
6.2	DIAGNOSTIC IMAGING	74
6.2.1	EASY ANALYSIS OF DISEASE CONDITIONS AND ACCURATE THERAPIES TO DRIVE MARKET	74
TABLE 14	THERANOSTICS MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2021-2028 (USD MILLION)	75
6.3	RADIOPHARMACEUTICALS	75
TABLE 15	THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	75
TABLE 16	THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY REGION, 2021-2028 (USD MILLION)	76
6.3.1	LUTETIUM-177	76
6.3.1.1	Increasing incidence of neuroendocrine cancer to boost segment	76
TABLE 17	LUTETIUM-177 MARKET, BY REGION, 2021-2028 (USD MILLION)	77
6.3.1.2	Samarium-153	77
6.3.1.3	Rising incidence of bone metastasis to drive segment growth	77
TABLE 18	SAMARIUM-153 MARKET, BY REGION, 2021-2028 (USD MILLION)	77
6.3.1.4	Radium-223	78

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.3.1.4.1	Easy production of Radium-223 molecule to support market growth	78
TABLE 19 RADIUM-223 MARKET, BY REGION, 2021-2028 (USD MILLION)		
6.3.1.5	Iodine-131	78
6.3.1.5.1	Increased applications in thyroid cancer and hyperthyroidism treatment to propel market	78
?		
TABLE 20 IODINE-131 MARKET, BY REGION, 2021-2028 (USD MILLION)		
6.3.1.6	Yttrium-90	79
6.3.1.6.1	Rising use in non-Hodgkin lymphoma and oncology radiotheranostics to drive segment	79
TABLE 21 YTTRIUM-90 MARKET, BY REGION, 2021-2028 (USD MILLION)		
6.3.1.7	Other radiopharmaceuticals	80
TABLE 22 OTHER RADIOPHARMACEUTICALS MARKET, BY REGION, 2021-2028 (USD MILLION)		
6.4	IVD/BIOMARKER SCREENING	80
6.4.1	RISING ADOPTION OF THERANOSTICS TREATMENT TO SUPPORT MARKET GROWTH	80
TABLE 23 THERANOSTICS MARKET FOR IVD/BIOMARKER SCREENING, BY REGION, 2021-2028 (USD MILLION)		
6.5	SOFTWARE & SERVICES	81
6.5.1	RISING USE OF NOVEL SOFTWARE AND INCREASING DEMAND FOR IMAGING SERVICES TO PROPEL MARKET	81
TABLE 24 THERANOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)		
7	THERANOSTICS MARKET, BY APPLICATION	83
7.1	INTRODUCTION	84
TABLE 25 THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)		
7.2	PROSTATE CANCER	84
7.2.1	RISING INCIDENCE OF PROSTATE CANCER AMONG MEN TO FUEL MARKET	84
TABLE 26 THERANOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021-2028 (USD MILLION)		
7.3	BONE METASTASIS	85
7.3.1	INTRODUCTION OF NOVEL MEDICAL THERAPIES TO DRIVE MARKET	85
TABLE 27 THERANOSTICS MARKET FOR BONE METASTASIS, BY REGION, 2021-2028 (USD MILLION)		
7.4	OTHER CANCERS	86
TABLE 28 THERANOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2021-2028 (USD MILLION)		
7.5	OTHER APPLICATIONS	87
TABLE 29 THERANOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)		
8	THERANOSTICS MARKET, BY END USER	88
8.1	INTRODUCTION	89
TABLE 30 THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)		
8.2	HOSPITALS AND CANCER CARE CENTERS	89
8.2.1	RISING TREND OF MODERNIZING IMAGING WORKFLOW SYSTEMS TO DRIVE MARKET	89
TABLE 31 THERANOSTICS MARKET FOR HOSPITALS AND CANCER CARE CENTERS, BY REGION, 2021-2028 (USD MILLION)		
?		
8.3	THERANOSTICS CENTERS	91
8.3.1	GROWING FOCUS ON TARGETED THERAPIES AND RISING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET	91
TABLE 32 THERANOSTICS MARKET FOR THERANOSTICS CENTERS, BY REGION, 2021-2028 (USD MILLION)		
8.4	RESEARCH AND ACADEMIC CENTERS	92
8.4.1	INCREASING COLLABORATIONS BETWEEN THERANOSTICS COMPANIES AND ACADEMIA TO SUPPORT MARKET GROWTH	92
TABLE 33 THERANOSTICS MARKET FOR RESEARCH AND ACADEMIC CENTERS, BY REGION, 2021-2028 (USD MILLION)		
9	THERANOSTICS MARKET, BY REGION	93
9.1	INTRODUCTION	94
TABLE 34 THERANOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)		
9.2	NORTH AMERICA	94

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 24	NORTH AMERICA: CANCER PREVALENCE, 2012-2020	95
FIGURE 25	NORTH AMERICA: THERANOSTICS MARKET SNAPSHOT (2022)	96
TABLE 35	NORTH AMERICA: THERANOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	96
TABLE 36	NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	97
TABLE 37	NORTH AMERICA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	97
TABLE 38	NORTH AMERICA: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	98
TABLE 39	NORTH AMERICA: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	98
9.3	NORTH AMERICA: RECESSION IMPACT	98
9.3.1	US	99
9.3.1.1	US to dominate North American theranostics market during forecast period	99
TABLE 40	US: KEY MACROINDICATORS	99
TABLE 41	US: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	100
TABLE 42	US: THERANOSTICS MARKET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	100
9.3.2	CANADA	101
9.3.2.1	Rising geriatric population and increasing number of initiatives for medical isotope development to drive market	101
TABLE 43	CANADA: KEY MACROINDICATORS	101
TABLE 44	CANADA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	102
TABLE 45	CANADA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	102
9.4	EUROPE	102
TABLE 46	EUROPE: THERANOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	103
TABLE 47	EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	103
TABLE 48	EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	104
TABLE 49	EUROPE: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	104
TABLE 50	EUROPE: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	104
9.4.1	EUROPE: RECESSION IMPACT	105
9.4.2	GERMANY	105
9.4.2.1	Well-established healthcare system and increased geriatric population to drive market	105
TABLE 51	GERMANY: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	106
TABLE 52	GERMANY: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	106
9.4.3	UK	107
9.4.3.1	Increasing government funding in diagnostic imaging to support market growth	107
TABLE 53	UK: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	108
TABLE 54	UK: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	108
9.4.4	FRANCE	108
9.4.4.1	Favorable government initiatives and high incidence of cancer to propel market	108
TABLE 55	FRANCE: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	109
TABLE 56	FRANCE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	110
9.4.5	REST OF EUROPE	110
TABLE 57	REST OF EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	111
TABLE 58	REST OF EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	111
9.5	ASIA PACIFIC	112
FIGURE 26	ASIA PACIFIC: CANCER PREVALENCE, 2012-2020	112
FIGURE 27	ASIA PACIFIC: THERANOSTICS MARKET SNAPSHOT (2022)	113
TABLE 59	ASIA PACIFIC: THERANOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	114
TABLE 60	ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	114
TABLE 61	ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	115
TABLE 62	ASIA PACIFIC: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	115

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 63	ASIA PACIFIC: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	116
9.5.1	ASIA PACIFIC: RECESSION IMPACT	116
9.5.2	JAPAN	116
9.5.2.1	Established nuclear medicine infrastructure and better accessibility of healthcare services to drive market	116
TABLE 64	JAPAN: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	117
TABLE 65	JAPAN: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	118
9.5.3	CHINA	118
9.5.3.1	Increasing number of government initiatives and growing geriatric population to drive market	118
TABLE 66	CHINA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	119
TABLE 67	CHINA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	119
9.5.4	INDIA	120
9.5.4.1	Rising number of nuclear medicine facilities and increasing incidence of chronic diseases to propel market	120
TABLE 68	INDIA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	121
TABLE 69	INDIA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	121
9.5.5	REST OF ASIA PACIFIC	121
TABLE 70	REST OF ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	122
TABLE 71	REST OF ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	123
9.6	REST OF THE WORLD	123
TABLE 72	REST OF THE WORLD: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	125
TABLE 73	REST OF THE WORLD: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)	125
TABLE 74	REST OF THE WORLD: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	126
TABLE 75	REST OF THE WORLD: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	126
9.6.1	REST OF THE WORLD: RECESSION IMPACT	126
10	COMPETITIVE LANDSCAPE	128
10.1	OVERVIEW	128
10.2	KEY STRATEGIES/RIGHT TO WIN	128
10.3	MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THERANOSTICS MARKET	129
FIGURE 28	KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN THERANOSTICS MARKET	129
10.4	REVENUE SHARE ANALYSIS	130
FIGURE 29	REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS, 2020-2022	130
10.5	MARKET SHARE ANALYSIS	130
FIGURE 30	ADVANCED ACCELERATOR APPLICATIONS COMMANDED LARGEST MARKET SHARE IN 2022	130
TABLE 76	DEGREE OF COMPETITION IN THERANOSTICS MARKET	131
10.6	COMPANY EVALUATION MATRIX	132
10.6.1	STARS	132
10.6.2	EMERGING LEADERS	132
10.6.3	PERVASIVE PLAYERS	132
10.6.4	PARTICIPANTS	132
FIGURE 31	COMPANY EVALUATION MATRIX, 2022	133
10.6.5	COMPANY FOOTPRINT	134
TABLE 77	PRODUCT AND REGIONAL FOOTPRINT	134
10.7	START-UP/SME EVALUATION MATRIX	134
10.7.1	PROGRESSIVE COMPANIES	134
10.7.2	RESPONSIVE COMPANIES	134
10.7.3	DYNAMIC COMPANIES	135
10.7.4	STARTING BLOCKS	135
FIGURE 32	START-UP/SME EVALUATION MATRIX, 2022	135

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.7.5	COMPETITIVE BENCHMARKING	136
TABLE 78	DETAILED LIST OF KEY START-UPS/SMES	136
10.8	COMPETITIVE SCENARIOS & TRENDS	136
11	COMPANY PROFILES	139
11.1	KEY PLAYERS	139
	(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*	
11.1.1	ADVANCED ACCELERATOR APPLICATIONS	139
TABLE 81	ADVANCED ACCELERATOR APPLICATIONS: COMPANY OVERVIEW	139
11.1.2	BAYER AG	142
TABLE 82	BAYER AG: COMPANY OVERVIEW	142
FIGURE 33	BAYER AG: COMPANY SNAPSHOT (2022)	142
11.1.3	GE HEALTHCARE	145
TABLE 83	GE HEALTHCARE: COMPANY OVERVIEW	145
FIGURE 34	GE HEALTHCARE: COMPANY SNAPSHOT (2022)	146
11.1.4	SIEMENS HEALTHINEERS AG	150
TABLE 84	SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW	150
FIGURE 35	SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)	151
11.1.5	CARDINAL HEALTH	154
TABLE 85	CARDINAL HEALTH: COMPANY OVERVIEW	154
FIGURE 36	CARDINAL HEALTH: COMPANY SNAPSHOT (2022)	155
11.1.6	PHILIPS HEALTHCARE	157
TABLE 86	PHILIPS HEALTHCARE: COMPANY OVERVIEW	157
FIGURE 37	PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2022)	158
11.1.7	CANON INC.	160
TABLE 87	CANON INC.: COMPANY OVERVIEW	160
FIGURE 38	CANON INC.: COMPANY SNAPSHOT (2022)	161
11.1.8	CURIUM	163
TABLE 88	CURIUM: COMPANY OVERVIEW	163
11.1.9	LANTHEUS	166
TABLE 89	LANTHEUS: COMPANY OVERVIEW	166
FIGURE 39	LANTHEUS: COMPANY SNAPSHOT (2022)	166
11.1.10	NORTHSTAR MEDICAL RADIOISOTOPES	168
TABLE 90	NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY OVERVIEW	168
11.1.11	ECKERT & ZIEGLER	171
TABLE 91	ECKERT & ZIEGLER: COMPANY OVERVIEW	171
FIGURE 40	ECKERT & ZIEGLER: COMPANY SNAPSHOT (2022)	171
11.1.12	PHARMALOGIC	174
TABLE 92	PHARMALOGIC: COMPANY OVERVIEW	174
11.1.13	ECZACIBASI-MONROL	176
TABLE 93	ECZACIBASI-MONROL: COMPANY OVERVIEW	176
11.1.14	ACROTECH BIOPHARMA, INC.	178
TABLE 94	ACROTECH BIOPHARMA, INC.: COMPANY OVERVIEW	178
11.2	OTHER PLAYERS	179
11.2.1	THERMO FISHER SCIENTIFIC INC.	179
11.2.2	GLOBAL MEDICAL SOLUTIONS	180
11.2.3	SHINE TECHNOLOGIES, LLC	181

11.2.4	ISOTOPIA MOLECULAR IMAGING LTD.	182
11.2.5	INSTITUTE OF ISOTOPES	183
11.2.6	CHINA ISOTOPE & RADIATION CORPORATION	184
11.2.7	YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.	185
11.2.8	ATOMVIE	186
11.2.9	ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH	186
11.2.10	TELEX PHARMACEUTICALS LIMITED	187
11.2.11	BLUE EARTH DIAGNOSTICS	187
11.2.12	SOFIE BIOSCIENCES	188
11.2.13	THERAGNOSTICS	188

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12	APPENDIX	189
12.1	DISCUSSION GUIDE	189
12.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	193
12.3	CUSTOMIZATION OPTIONS	195
12.4	RELATED REPORTS	195
12.5	AUTHOR DETAILS	196

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI),
Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening,
Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder
Expectations - Global Forecast to 2028**

Market Report | 2024-01-30 | 194 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature